[go: up one dir, main page]

AR061985A1 - Composiciones farmaceuticas orales, particularmente aptas para aliviar resfrios, tos, gripe, fiebre, jaqueca, dolor, dolor corporal, migraña o sintomas alergicos - Google Patents

Composiciones farmaceuticas orales, particularmente aptas para aliviar resfrios, tos, gripe, fiebre, jaqueca, dolor, dolor corporal, migraña o sintomas alergicos

Info

Publication number
AR061985A1
AR061985A1 ARP070103111A ARP070103111A AR061985A1 AR 061985 A1 AR061985 A1 AR 061985A1 AR P070103111 A ARP070103111 A AR P070103111A AR P070103111 A ARP070103111 A AR P070103111A AR 061985 A1 AR061985 A1 AR 061985A1
Authority
AR
Argentina
Prior art keywords
pain
oral pharmaceutical
jaqueca
tos
flu
Prior art date
Application number
ARP070103111A
Other languages
English (en)
Inventor
Bubnis William
Shield Stephanie
P Hoskovec Gayle
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38814551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061985(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR061985A1 publication Critical patent/AR061985A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica líquida, oral, que comprende fenilefrina y polietilenglicol sustancialmente libre de aldehídos. La composición tiene fenilefrina compatible establemente con la requerida estabilidad para preparaciones comerciales. Opcionalmente, la composición puede comprender uno o más agentes activos adicionales como por ejemplo, dextrometorfan, guaifenesina, acetaminofen, maleato de clorfeniramina, etc..
ARP070103111A 2006-07-14 2007-07-13 Composiciones farmaceuticas orales, particularmente aptas para aliviar resfrios, tos, gripe, fiebre, jaqueca, dolor, dolor corporal, migraña o sintomas alergicos AR061985A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/487,120 US20080014274A1 (en) 2006-07-14 2006-07-14 Enhanced stability phenylephrine liquid compositions

Publications (1)

Publication Number Publication Date
AR061985A1 true AR061985A1 (es) 2008-08-10

Family

ID=38814551

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103111A AR061985A1 (es) 2006-07-14 2007-07-13 Composiciones farmaceuticas orales, particularmente aptas para aliviar resfrios, tos, gripe, fiebre, jaqueca, dolor, dolor corporal, migraña o sintomas alergicos

Country Status (26)

Country Link
US (1) US20080014274A1 (es)
EP (2) EP2040672B1 (es)
JP (1) JP2009543777A (es)
KR (2) KR20090040334A (es)
CN (2) CN104546671A (es)
AR (1) AR061985A1 (es)
AU (1) AU2007272961B2 (es)
BR (1) BRPI0714399B8 (es)
CA (1) CA2657611A1 (es)
CO (1) CO6180496A2 (es)
EC (1) ECSP099072A (es)
ES (2) ES2537761T3 (es)
HK (1) HK1205933A1 (es)
HU (2) HUE025694T2 (es)
IL (1) IL196447A (es)
MX (1) MX2009000530A (es)
NZ (1) NZ574148A (es)
PE (1) PE20081003A1 (es)
PL (2) PL2351554T3 (es)
PT (2) PT2351554E (es)
RU (1) RU2468787C2 (es)
SG (2) SG173354A1 (es)
TW (1) TW200812640A (es)
UY (1) UY30484A1 (es)
WO (1) WO2008008364A2 (es)
ZA (1) ZA200900315B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
TWI411451B (zh) * 2006-06-01 2013-10-11 Msd Consumer Care Inc 用於結腸吸收之脫羥腎上腺素醫藥調配物及組合物
CA2653955C (en) * 2006-06-01 2015-10-27 Schering Corporation Pharmaceutical compositions for sustained release of phenylephrine
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
US20070281019A1 (en) * 2006-06-01 2007-12-06 Ulloa Sergio R Phenylephrine pulsed release formulations and pharmaceutical compositions
BRPI0812784A2 (pt) * 2007-06-01 2014-12-02 Schering Plough Healthcare Composição farmacêutica compreendendo um substrato e um revestimento contendo um ingrediente ativo e polivinilálcool
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
US8518439B2 (en) * 2008-12-03 2013-08-27 Novartis Ag Liquid therapeutic composition
CA2690488C (en) * 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
CA2802362C (en) * 2010-06-11 2017-11-21 Gm Pharmaceuticals, Inc. Pharmaceutical compositions for alleviating upper respiratory and oral-pharyngeal congestion
KR20190085561A (ko) 2010-10-21 2019-07-18 알티유 파머수티컬즈, 엘엘시 즉시 사용가능한 케토로락 제제
FR2987268B1 (fr) * 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
CN105007891B (zh) * 2013-02-28 2018-01-16 辉瑞公司 新液体组合物的增强的稳定性
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
GB201506755D0 (en) * 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
JP5918895B1 (ja) * 2015-05-21 2016-05-18 富士カプセル株式会社 ナルフラフィン塩酸塩含有カプセル製剤
AU2016270504A1 (en) * 2015-05-29 2017-12-14 Codadose Incorporated Liquid formulations of celecoxib for oral administration
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
WO2018045170A1 (en) * 2016-09-01 2018-03-08 The Procter & Gamble Company Medication with improved taste and sensory experience
PL3515413T3 (pl) 2016-09-26 2023-11-13 The Procter & Gamble Company Postać dawkowania zapewniająca przedłużoną ulgę
CN110115708A (zh) * 2018-02-07 2019-08-13 保瑞药业股份有限公司 乙酰胺酚及曲马多共溶复方止痛口服液
CR20200552A (es) 2018-05-16 2021-05-13 Bayer Healthcare Llc Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe
CN108434097A (zh) * 2018-06-22 2018-08-24 南京济群医药科技股份有限公司 一种稳定的含盐酸曲普利啶口服溶液剂及其制备方法
CN109010341A (zh) * 2018-10-29 2018-12-18 南京济群医药科技股份有限公司 一种含有氢溴酸右美沙芬的复方口服溶液及其制备方法
MX2021012356A (es) 2019-04-11 2021-11-04 Scherer Technologies Llc R P Formulación para suministro oral de proteínas, péptidos y moléculas pequeñas con poca permeabilidad.
CA3164495C (en) 2019-12-23 2024-11-05 Nutra Essential Otc, S.L. LIQUID COMPOSITION CONTAINING IBUPROFEN AND PHENYLEPHRINE
WO2021150747A1 (en) * 2020-01-22 2021-07-29 Nevakar Inc. Phenylephrine hydrochloride compositions and containers
CN111773203B (zh) * 2020-05-15 2024-11-26 北京博智绿洲医药科技有限公司 一种包含盐酸去氧肾上腺素组合物的制备工艺
CN114533664B (zh) * 2022-01-29 2023-03-31 江苏广承药业有限公司 一种氢溴酸右美沙芬和愈创木酚甘油醚复方口服液体制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3515781A (en) * 1967-10-12 1970-06-02 Johnson & Johnson Cold capsule
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
DE69815003T2 (de) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
US6287597B1 (en) 1999-03-12 2001-09-11 Carter-Wallace, Inc. Antihistaminic/decongestant compositions
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
BR0211794A (pt) 2001-07-31 2004-11-03 Wyeth Corp Composição farmacêutica e método para mascarar o sabor de pelo menos um composto farmaceuticamente ativo de sabor desagradável
US6462094B1 (en) * 2001-08-22 2002-10-08 Medpointe Healthcare Inc. Decongestant/expectorant compositions
US20030060422A1 (en) * 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
US6509492B1 (en) * 2001-08-31 2003-01-21 First Horizon Pharmaceutical Corporation Tannate compositions and methods of treatment
US20040132827A1 (en) 2001-10-26 2004-07-08 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
EP1559433A4 (en) 2002-10-22 2009-11-04 Dainippon Sumitomo Pharma Co STABILIZED COMPOSITION
US6979689B2 (en) 2002-12-20 2005-12-27 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
JP2004300138A (ja) * 2003-03-18 2004-10-28 Takeda Chem Ind Ltd 安定化された経口固形製剤
US20050152967A1 (en) 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
DE10358213A1 (de) 2003-12-12 2005-07-28 Clariant Gmbh Polyethylenglykol und dessen Herstellung
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
WO2006022996A2 (en) 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20060148837A1 (en) 2005-01-04 2006-07-06 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20070098785A1 (en) * 2005-11-02 2007-05-03 Tim Clarot Medicant delivery system and device
US20070160689A1 (en) * 2006-01-12 2007-07-12 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20070254027A1 (en) 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness

Also Published As

Publication number Publication date
SG173354A1 (en) 2011-08-29
ES2550036T3 (es) 2015-11-04
PE20081003A1 (es) 2008-07-13
CO6180496A2 (es) 2010-07-19
HK1128886A1 (en) 2009-11-13
BRPI0714399A2 (pt) 2013-03-12
UY30484A1 (es) 2008-02-29
IL196447A0 (en) 2009-09-22
TW200812640A (en) 2008-03-16
RU2468787C2 (ru) 2012-12-10
JP2009543777A (ja) 2009-12-10
MX2009000530A (es) 2009-01-27
KR20140088234A (ko) 2014-07-09
IL196447A (en) 2015-06-30
ECSP099072A (es) 2009-02-27
CA2657611A1 (en) 2008-01-17
ES2537761T3 (es) 2015-06-11
US20080014274A1 (en) 2008-01-17
BRPI0714399B8 (pt) 2021-05-25
PT2351554E (pt) 2015-11-02
PL2351554T3 (pl) 2016-01-29
PL2040672T3 (pl) 2015-07-31
EP2351554A1 (en) 2011-08-03
EP2351554B1 (en) 2015-09-09
RU2009101295A (ru) 2010-08-27
BRPI0714399B1 (pt) 2020-11-17
EP2040672A2 (en) 2009-04-01
KR20090040334A (ko) 2009-04-23
HUE025790T2 (hu) 2016-05-30
ZA200900315B (en) 2009-12-30
EP2040672B1 (en) 2015-04-01
PT2040672E (pt) 2015-07-02
CN104546671A (zh) 2015-04-29
SG10201408522UA (en) 2015-02-27
AU2007272961B2 (en) 2011-07-28
HK1205933A1 (en) 2015-12-31
WO2008008364A2 (en) 2008-01-17
AU2007272961A1 (en) 2008-01-17
NZ574148A (en) 2012-07-27
WO2008008364A3 (en) 2008-05-22
HUE025694T2 (hu) 2016-04-28
CN101500539A (zh) 2009-08-05

Similar Documents

Publication Publication Date Title
AR061985A1 (es) Composiciones farmaceuticas orales, particularmente aptas para aliviar resfrios, tos, gripe, fiebre, jaqueca, dolor, dolor corporal, migraña o sintomas alergicos
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
CL2020000468A1 (es) Uso de una formulación estable que comprende una enzima de reemplazo para la enzima lisosomal (divisional solicitud 201801220)
CL2009001936A1 (es) Compuestos derivados de piridazina, inhibidores de 11beta-hsd1; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de la diabetes, obesidad, dislipidemia, trastornos de ingestion de comida e hipertension (divisional de solicitud 1720-2006).
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
AR033023A1 (es) Composicion topica
BRPI0414581C1 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
AR093115A1 (es) Soluciones midriaticas y antiinflamatorias inyectables, estables y libres de conservantes
CL2009000882A1 (es) Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer.
PE20110010A1 (es) Formulaciones liquidas de fenilefrina
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
ECSP077261A (es) Composición de anticuerpo her2
EP2019857A4 (en) Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
ECSP088903A (es) Composiciones farmacéuticas de anticuerpo antagonista anti-cd40
ATE509636T1 (de) Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität
CL2008003537A1 (es) Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
NI201000189A (es) Formulación de medicamento sólido con liberación retardadas.
EA201170512A1 (ru) Композиция для перорального введения
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
UA87841C2 (ru) Композиция, которая содержит амброксол, для местного применения
CL2008001810A1 (es) Compuestos derivados de espiroindolinas, moduladores de receptores de quimiocinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar aterosclerosis, dolor inflamatorio, influenza, sindrome metabolico, entre otras enfermedades.

Legal Events

Date Code Title Description
FB Suspension of granting procedure